ロード中...
Exposure−response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes
AIMS: To provide model-based clinical development decision support including dose selection guidance for empagliflozin, an orally administered sodium glucose cotransporter 2 inhibitor, through developed exposure−response (E−R) models for efficacy and tolerability in patients with type 2 diabetes mel...
保存先:
| 出版年: | Br J Clin Pharmacol |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BlackWell Publishing Ltd
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4256629/ https://ncbi.nlm.nih.gov/pubmed/24964723 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12453 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|